MALT1 protease: A new therapeutic target in B lymphoma and beyond?

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6623-6631

  McAllister Lucas, Linda M ^a   Baens, Mathijs ^c,d   Lucas, Peter C ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE RECEPTOR ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA BLOCKING AGENT; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATION 1 PROTEINASE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATION 1 PROTEINASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; B CELL LYMPHOMA; CARCINOGENESIS; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; GENE IDENTIFICATION; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LARGE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATION 1 GENE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; TH17 CELL; TUMOR GENE;

ANIMALS; CASPASES; GENE KNOCKOUT TECHNIQUES; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PROTEASE INHIBITORS;

EID: 80455144540     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0467     Document Type: Review

References (65)

1. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21; q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999;93:3601-9. (Pubitemid 29249804)
2. Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H, et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999;18:5785-94. (Pubitemid 29507432)
3. Morgan JA, Yin Y, Borowsky AD, Kuo F, Nourmand N, Koontz JI, et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 1999; 59:6205-13. (Pubitemid 30035644)
4. Lucas PC, Yonezumi M, Inohara N, McAllister-Lucas LM, Abazeed ME, Chen FF, et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem 2001;276:19012-9.
5. Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV, et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 2000;6:961-7.
6. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-53. (Pubitemid 39025059)
7. Noels H, van Loo G, Hagens S, Broeckx V, Beyaert R, Marynen P, et al. A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions. J Biol Chem 2007;282:10180-9. (Pubitemid 47093445)
8. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004;14:289-301. (Pubitemid 38591401)
9. Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DSL, Siu K, et al. A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment. Oncogene 2007;26:5643-54. (Pubitemid 47267834)
10. Zhou H, Du MQ, Dixit VM. Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 2005;7:425-31. (Pubitemid 40719126)
11. Garrison JB, Samuel T, Reed JC. TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB. Oncogene 2009;28:1584-93.
12. Zhou H, Wertz I, O'Rourke K, Ultsch M, Seshagiri S, Eby M, et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 2004;427:167-71. (Pubitemid 38094958)
13. Wu CJ, Ashwell JD. NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation. Proc Natl Acad Sci U S A 2008;105:3023-8. (Pubitemid 351723661)
14. Oeckinghaus A, Wegener E, Welteke V, Ferch U, Arslan SC, Ruland J, et al. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J 2007;26:4634-45. (Pubitemid 350126802)
15. Ruland J, Duncan GS, Wakeham A, Mak TW. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 2003;19: 749-58. (Pubitemid 37490799)
16. Ruefli-Brasse AA, French DM, Dixit VM. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 2003;302:1581-4. (Pubitemid 37475705)
17. Sommer K, Guo B, Pomerantz JL, Bandaranayake AD, Moreno-García ME, Ovechkina YL, et al. Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity 2005;23:561-74. (Pubitemid 41779479)
18. Matsumoto R, Wang D, Blonska M, Li H, Kobayashi M, Pappu B, et al. Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation. Immunity 2005;23:575-85. (Pubitemid 41779480)
19. Park SG, Schulze-Luehrman J, Hayden MS, Hashimoto N, Ogawa W, Kasuga M, et al. The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-kappaB and activate T cells. Nat Immunol 2009;10:158-66.
20. Lee KY, D'Acquisto F, Hayden MS, Shim JH, Ghosh S. PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. Science 2005;308:114-8. (Pubitemid 40471010)
21. Ferch U, zum Büschenfelde CM, Gewies A, Wegener E, Rauser S, Peschel C, et al. MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit. Nat Immunol 2007;8:984-91. (Pubitemid 47300013)
22. Tusche MW, Ward LA, Vu F, McCarthy D, Quintela-Fandino M, Ruland J, et al. Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets. J Exp Med 2009;206:2671-83.
23. Klemm S, Gutermuth J, Hültner L, Sparwasser T, Behrendt H, Peschel C, et al. The Bcl10-Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine production from mast cell degranulation. J Exp Med 2006;203:337-47. (Pubitemid 43290843)
24. Dong W, Liu Y, Peng J, Chen L, Zou T, Xiao H, et al. The IRAK-1- BCL10-MALT1-TRAF6-TAK1 cascade mediates signaling to NF-kappaB from Toll-like receptor 4. J Biol Chem 2006;281: 26029-40. (Pubitemid 44401809)
25. Gross O, Gewies A, Finger K, Schäfer M, Sparwasser T, Peschel C, et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006;442:651-6. (Pubitemid 44215314)
26. Gringhuis SI, Wevers BA, Kaptein TM, van Capel TMM, Theelen B, Boekhout T, et al. Selective C-Rel activation via Malt1 controls antifungal T(H)-17 immunity by dectin-1 and dectin-2. PLoS Pathog 2011;7:e1001259.
27. Gross O, Grupp C, Steinberg C, Zimmermann S, Strasser D, Hannesschläger N, et al. Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production. Blood 2008;112: 2421-8.
28. Klemm S, Zimmermann S, Peschel C, Mak TW, Ruland J. Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation and cytokine production. Proc Natl Acad Sci U S A 2007;104:134-8. (Pubitemid 46067997)
29. McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DSL, et al. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci U S A 2007;104:139-44. (Pubitemid 46067998)
30. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009;284: 6038-42.
31. Rehman AO, Wang CY. CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex. Int J Oral Sci 2009;1:105-18.
32. Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM, et al. Thrombin-dependent NF-kappaB activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome. J Biol Chem 2010;285:41432-42.
33. Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z, Huang S. Protein kinase C alpha-CARMA3 signaling axis links Ras to NFkappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 2008;27: 1273-80. (Pubitemid 351294695)
34. McAllister-Lucas LM, Jin X, Gu S, Siu K, McDonnell S, Ruland J, et al. The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J Biol Chem 2010;285:25880-4.
35. Snipas SJ, Wildfang E, Nazif T, Christensen L, Boatright KM, Bogyo M, et al. Characteristics of the caspase-like catalytic domain of human paracaspase. Biol Chem 2004;385:1093-8. (Pubitemid 39600319)
36. Rebeaud F, Hailfinger S, Posevitz-Fejfar A, Tapernoux M, Moser R, Rueda D, et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol 2008;9:272-81. (Pubitemid 351267324)
37. Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 2008;9:263-71. (Pubitemid 351267323)
38. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004;430:694-9. (Pubitemid 39061687)
39. Düwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, et al. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol 2009;182:7718-28.
40. Harhaj EW, Dixit VM. Deubiquitinases in the regulation of NF-kB signaling. Cell Res 2011;21:22-39.
41. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717-21.
42. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-6.
43. Dong G, Chanudet E, Zeng N, Appert A, Chen YW, Au WY, et al. A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. Clin Cancer Res 2011;17:1440-51.
44. Malinverni C, Unterreiner A, Staal J, Demeyer A, Galaup M, Luyten M, et al. Cleavage by MALT1 induces cytosolic release of A20. Biochem Biophys Res Commun 2010;400:543-7.
45. Staal J, Driege Y, Bekaert T, Demeyer A, Muyllaert D, Van Damme P, et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J 2011;30:1742-52.
46. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000;25:160-5. (Pubitemid 30394985)
47. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Lymphoma/ Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-23.
48. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006;441:106-10.
49. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676-9. (Pubitemid 351432507)
50. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
51. Ferch U, Kloo B, Gewies A, Pfänder V, Düwel M, Peschel C, et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2009;206: 2313-20.
52. Hailfinger S, Lenz G, Ngo V, Posvitz-Fejfar A, Rebeaud F, Guzzardi M, et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2009;106: 19946-51.
53. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-9.
54. Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011;331:468-72.
55. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006;25:6680-4. (Pubitemid 44657845)
56. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-30. (Pubitemid 47199123)
57. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004;279:26243-50. (Pubitemid 38798772)
58. Wilson CGM, Arkin MR. Small-molecule inhibitors of IL-2/IL-2R: lessons learned and applied. Curr Top Microbiol Immunol 2011;348: 25-59.
59. Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 2007;27:1-18. (Pubitemid 46224930)
60. Crispín JC, Tsokos GC. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun Rev 2009;8:190-5.
61. Josefowicz SZ, Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009;30:616-25.
62. Hemdan NYA, Birkenmeier G, Wichmann G, Abu El-Saad AM, Krieger T, Conrad K, et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev 2010;9:785-92.
63. Castro HC, Abreu PA, Geraldo RB, Martins RC, dos Santos R, Loureiro NI, et al. Looking at the proteases from a simple perspective. J Mol Recognit 2011;24:165-81.
64. Drag M, Salvesen GS. Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 2010;9:690-701.
65. Hailfinger S, Nogai H, Pelzer C, Jaworski M, Cabalzar K, Charton JE, et al. Malt1-dependent RelB cleavage promotes canonical NF-{kappa} B activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci U S A 2011;108:14596-601.